147 related articles for article (PubMed ID: 25013471)
1. Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer.
Kim SC; Kim MK; Kim YH; Ahn SA; Kim KH; Kim K; Kim WK; Lee JH; Cho JY; Yoo BC
Oncol Lett; 2014 Aug; 8(2):566-574. PubMed ID: 25013471
[TBL] [Abstract][Full Text] [Related]
2. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.
Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC
Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848
[TBL] [Abstract][Full Text] [Related]
3. Low-mass-ion discriminant equation (LOME) for ovarian cancer screening.
Lee JH; Yoo BC; Kim YH; Ahn SA; Yeo SG; Cho JY; Kim KH; Kim SC
BioData Min; 2016; 9():32. PubMed ID: 27752286
[TBL] [Abstract][Full Text] [Related]
4. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening.
Lee JH; Kim KH; Park JW; Chang HJ; Kim BC; Kim SY; Kim KG; Lee ES; Kim DY; Oh JH; Yoo BC; Kim IH
Int J Cancer; 2014 Apr; 134(8):1844-53. PubMed ID: 24096867
[TBL] [Abstract][Full Text] [Related]
5. Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare.
Lee JH; Yu SE; Kim KH; Yu MH; Jeong IH; Cho JY; Park SJ; Lee WJ; Han SS; Kim TH; Hong EK; Woo SM; Yoo BC
EPMA J; 2018 Sep; 9(3):287-297. PubMed ID: 30174764
[TBL] [Abstract][Full Text] [Related]
6. MALDI-TOF Mass Spectrometry Based on Parylene-Matrix Chip for the Analysis of Lysophosphatidylcholine in Sepsis Patient Sera.
Park JM; Noh JY; Kim MJ; Yun TG; Lee SG; Chung KS; Lee EH; Shin MH; Ku NS; Yoon S; Kang MJ; Park MS; Pyun JC
Anal Chem; 2019 Nov; 91(22):14719-14727. PubMed ID: 31621295
[TBL] [Abstract][Full Text] [Related]
7. The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.
Tamir A; Gangadharan A; Balwani S; Tanaka T; Patel U; Hassan A; Benke S; Agas A; D'Agostino J; Shin D; Yoon S; Goy A; Pecora A; Suh KS
J Ovarian Res; 2016 Mar; 9():20. PubMed ID: 27036110
[TBL] [Abstract][Full Text] [Related]
8. Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling.
Yoo BC; Kong SY; Jang SG; Kim KH; Ahn SA; Park WS; Park S; Yun T; Eom HS
BMC Cancer; 2010 Feb; 10():55. PubMed ID: 20175931
[TBL] [Abstract][Full Text] [Related]
9. Identification of hypoxanthine and phosphoenolpyruvic Acid as serum markers of chemoradiotherapy response in locally advanced rectal cancer.
Kim K; Yeo SG; Yoo BC
Cancer Res Treat; 2015 Jan; 47(1):78-89. PubMed ID: 25143052
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of ovarian tumor classification by improved reproducibility in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of serum glycans.
Park CW; Jo Y; Jo EJ
Anal Biochem; 2013 Dec; 443(1):58-65. PubMed ID: 23969014
[TBL] [Abstract][Full Text] [Related]
11. The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling.
Longuespée R; Boyon C; Castellier C; Jacquet A; Desmons A; Kerdraon O; Vinatier D; Fournier I; Day R; Salzet M
Histochem Cell Biol; 2012 Jul; 138(1):141-54. PubMed ID: 22532226
[TBL] [Abstract][Full Text] [Related]
12. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric screening of ovarian cancer with serum glycans.
Kim JH; Park CW; Um D; Baek KH; Jo Y; An H; Kim Y; Kim TJ
Dis Markers; 2014; 2014():634289. PubMed ID: 24648610
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.
Callesen AK; Christensen Rd; Madsen JS; Vach W; Zapico E; Cold S; Jørgensen PE; Mogensen O; Kruse TA; Jensen ON
Rapid Commun Mass Spectrom; 2008; 22(3):291-300. PubMed ID: 18181248
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous Analysis of Multiple Cancer Biomarkers Using MALDI-TOF Mass Spectrometry Based on a Parylene-Matrix Chip.
Park JM; Kim MJ; Noh JY; Yun TG; Kang MJ; Lee SG; Yoo BC; Pyun JC
J Am Soc Mass Spectrom; 2020 Apr; 31(4):917-926. PubMed ID: 32154716
[TBL] [Abstract][Full Text] [Related]
16. Seven low-mass ions in pretreatment serum as potential predictive markers of the chemoradiotherapy response of rectal cancer.
Roh K; Yeo SG; Yoo BC; Kim KH; Kim SY; Kim MJ
Anticancer Drugs; 2016 Sep; 27(8):787-93. PubMed ID: 27272410
[TBL] [Abstract][Full Text] [Related]
17. Predict ovarian cancer by pairing serum miRNAs: Construct of single sample classifiers.
Hong G; Luo F; Chen Z; Ma L; Lin G; Wu T; Li N; Cai H; Hu T; Zhong H; Guo Y; Li H
Front Med (Lausanne); 2022; 9():923275. PubMed ID: 35983098
[TBL] [Abstract][Full Text] [Related]
18. Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival.
Kim KH; Joo J; Park B; Park SJ; Lee WJ; Han SS; Kim TH; Hong EK; Woo SM; Yoo BC
Oncotarget; 2017 Dec; 8(68):112598-112609. PubMed ID: 29348849
[TBL] [Abstract][Full Text] [Related]
19. Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry.
Li F; Qin X; Chen H; Qiu L; Guo Y; Liu H; Chen G; Song G; Wang X; Li F; Guo S; Wang B; Li Z
Rapid Commun Mass Spectrom; 2013 Jan; 27(1):24-34. PubMed ID: 23239314
[TBL] [Abstract][Full Text] [Related]
20. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
